Ono Pharmaceutical Co., Ltd.
OPHLF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $876 | $127,536 | $112,309 | $134,223 |
| % Growth | -99.3% | 13.6% | -16.3% | – |
| Cost of Goods Sold | $236 | $37,013 | $45,237 | $45,836 |
| Gross Profit | $640 | $90,523 | $67,072 | $88,387 |
| % Margin | 73% | 71% | 59.7% | 65.9% |
| R&D Expenses | $235 | $36,252 | $42,794 | $38,269 |
| G&A Expenses | $0 | $0 | $1,211 | $0 |
| SG&A Expenses | $203 | $31,086 | $31,932 | $35,315 |
| Sales & Mktg Exp. | $0 | $0 | $30,651 | $0 |
| Other Operating Expenses | $0 | $1,190 | $3,353 | -$70 |
| Operating Expenses | $438 | $68,528 | $78,079 | $73,514 |
| Operating Income | $201 | $21,995 | -$11,007 | $14,873 |
| % Margin | 23% | 17.2% | -9.8% | 11.1% |
| Other Income/Exp. Net | -$2 | $655 | -$1,701 | $2,527 |
| Pre-Tax Income | $200 | $22,650 | -$12,708 | $17,400 |
| Tax Expense | $48 | $5,019 | -$6,341 | $2,514 |
| Net Income | $152 | $17,673 | -$6,545 | $14,951 |
| % Margin | 17.4% | 13.9% | -5.8% | 11.1% |
| EPS | 0.32 | 37.62 | -13.93 | 31.83 |
| % Growth | -99.1% | 370.1% | -143.8% | – |
| EPS Diluted | 0.32 | 37.58 | -13.97 | 31.81 |
| Weighted Avg Shares Out | 470 | 470 | 466 | 470 |
| Weighted Avg Shares Out Dil | 470 | 470 | 470 | 470 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $655 | $0 | $2,526 |
| Interest Expense | $8 | $0 | $1,824 | $0 |
| Depreciation & Amortization | $63 | $9,238 | $8,728 | $9,170 |
| EBITDA | $271 | $31,233 | -$5,788 | $24,045 |
| % Margin | 30.9% | 24.5% | -5.2% | 17.9% |